Advertisement

American Journal of Clinical Dermatology

, Volume 14, Issue 5, pp 359–376 | Cite as

Treatment of Melasma with Topical Agents, Peels and Lasers: An Evidence-Based Review

  • Shelly Rivas
  • Amit G. PandyaEmail author
Evidence-Based Review

Abstract

Background

Melasma is an acquired disorder of hyperpigmentation occurring on the face and predominantly affecting women of childbearing age. It is a chronic, often relapsing condition with a negative impact on quality of life. Current treatments for melasma are unsatisfactory.

Objective

The aim of this article was to conduct an evidence-based review of interventions available for the treatment of melasma.

Methods

A systematic literature search was performed using PubMed and the keywords ‘melasma’ or ‘chloasma’ in the title. The search was further refined by using a filter for ‘controlled clinical trials’ and ‘randomized controlled trial’. The included studies were used to develop recommendations for treatment.

Results

The electronic search yielded a total of 80 citations. Forty studies were included in this review, which had a total of 2,912 participants. Three different therapeutic modalities were investigated—topical agents, chemical peels, and laser and light therapies. Topical depigmenting agents were found to be the most effective in treating moderate-to-severe melasma, with combination therapies, such as triple-combination therapy (hydroquinone, tretinoin, and fluocinolone acetonide), yielding the best results. Chemical peels as well as laser and light therapies were found to have moderate benefit but more studies are needed to determine their efficacy and long-term safety. Adverse events associated with treatment were mild and short-lasting and included skin irritation, dryness, burning, and erythema. The data could not be statistically pooled because of the heterogeneity of treatments and lack of consistency across study designs.

Conclusions

Topical combination therapies were found to be more effective than monotherapy. Triple combination therapy was found to be the most effective, but approximately 40 % of patients develop erythema and peeling. Chemical peels and laser and light therapies produced mixed results, with increased risk of irritation and subsequent hyperpigmentation, particularly in darker-skinned individuals. Hence, current treatments available for melasma remain unsatisfactory. Many of the studies lacked long-term follow-up. Limitations of current literature include the heterogeneity of study designs, small sample sizes, and poor follow-up rates. Additional evidence for the effects and role of sunscreens is needed. Categorization or stratification of demographic data should also be included in future studies, such as age, melasma type, and duration of melasma prior to initiation of treatment. Patient’s perception of improvement versus investigator’s assessment of improvement should also be included in future studies and standardized methods of study design and assessment of outcomes are needed to form definitive conclusions on the efficacy of different treatment modalities.

Keywords

Hydroquinone Tretinoin Glycolic Acid Azelaic Acid Kojic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

No sources of funding were used to prepare this article. Dr Pandya receives consulting fees from Galderma for his role in the Pigmentary Disorders Academy. The authors have no other conflicts of interest that are directly relevant to the content of this article.

References

  1. 1.
    Grimes PE. Melasma: etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Resnik S. Melasma induced by oral contraceptive drugs. JAMA. 1967;199:601–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Ponzio HA, Favaretto AL, Rivitti EA. Proposal of a quantitative method to describe melasma distribution in women. J Cosmet Dermatol. 2007;20:103–11.Google Scholar
  4. 4.
    Pathak MA, Riley FC, Fitzpatrick TB. Melanogenesis in human skin following exposure to long ultraviolet and visible light. J Invest Dermatol. 1962;39:435.PubMedGoogle Scholar
  5. 5.
    Ortonne JP, Arellano I, Berneburg M, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol. 2009;23:1254–62.PubMedCrossRefGoogle Scholar
  6. 6.
    Sanchez NP, Pathak MA, Sato S. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4:698–709.PubMedCrossRefGoogle Scholar
  7. 7.
    Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev. 2010;7(7).Google Scholar
  8. 8.
    Ennes SBP, Paschoalick RC, De Avelar Alchorne MM. A double-blind comparative placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma. J Dermatol Treat. 2000;11:173–9.Google Scholar
  9. 9.
    Vázquez M, Sánchez JL. The efficacy of a broad-spectrum sunscreen in the treatment of melasma. Cutis. 1983;32:92–6.PubMedGoogle Scholar
  10. 10.
    Baliña LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30:893–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Sivayathorn A, Verallo-Rowell V, Graupe K. 20% azelaic acid cream in the topical treatment of melasma: a double- blind comparison with 2% hydroquinone. Eur J Dermatol. 1995;5:680–4.Google Scholar
  12. 12.
    Farshi S. Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma. J Cosmet Dermatol. 2011;10:282–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol. 2004;43(8):604–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Huh CH, Seo KI, Park JY, Lim JG, Eun HC, Park KC. A randomized, double-blind, placebo-controlled trial of Vitamin C iontophoresis in melasma. Dermatology. 2003;206:316–20.PubMedCrossRefGoogle Scholar
  15. 15.
    Khemis A, Kaiafa A, Queille-Roussel C, Duteil L, Ortonne JP. Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial. Br J Dermaol. 2007;156:997–1004.CrossRefGoogle Scholar
  16. 16.
    Huh SY, Shin JW, Na JI, et al. Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial. J Dermatol. 2010;37:311–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Thirion L, Pierard-Franchimont C, Pierard G. Whitening effect of a dermocosmetic formulation: a randomized double-blind controlled study on melasma. Int J Cosmet Sci. 2006;28:263–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Francisco-Diaz J, Cristi-Cataluna I, Cruz DD, Verallo-Rowell VM. A double-blind randomized placebo controlled trial on the efficacy and safety of botanical extract (Gigawhite® 5% solution) in the treatment of melasma. J Phil Dermatol Soc. 2004;13:18–23.Google Scholar
  19. 19.
    Ortonne JP. Retinoid therapy of pigmented disorders. Dermatol Ther. 2006;19:280–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Romero C, Aberdam E, Larnier C, Ortonne JP. Retinoic acid as modulator of UVB-induced melanocyte differentiation. Involvement of the melanogenic enzymes expression. J Cell Sci. 1994;107:1095–103.PubMedGoogle Scholar
  21. 21.
    Griffiths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol. 1993;129:415–21.PubMedCrossRefGoogle Scholar
  22. 22.
    Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, et al. Topical retinoic acid (tretinoin) for melasma in black patients. Arch Dermatol. 1994;130:727–33.PubMedCrossRefGoogle Scholar
  23. 23.
    Leenutaphong V, Nettakul A, Rattanasuwon P. Topical isotretinoin for melasma in Thai patients: a vehicle-controlled clinical trial. J Med Assoc Thai. 1999;82:868–74.PubMedGoogle Scholar
  24. 24.
    Kanechorn NA, Niumphradit N, Manosroi A, Nakakes A. Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial. J Cosmet Laser Ther. 2012;14:150–4.CrossRefGoogle Scholar
  25. 25.
    Lee MH, Kim HJ, Ha DJ, et al. Therapeutic effect of topical of linoleic acid and lincomycin in combination with betamethasone valerate in melasma patients. J Korean Med Sci. 2002;17:518–23.PubMedGoogle Scholar
  26. 26.
    Alvin G, Catambay N, Vergara A, Jamora MJ. A comparative study of the safety and efficacy of 75% mulberry (Morus alba) extract oil versus placebo as a topical treatment for melasma: a randomized, single-blind, placebo-controlled trial. J Drugs Dermatol. 2011;10:1025–31.PubMedGoogle Scholar
  27. 27.
    Altaei T. The treatment of melasma by silymarin cream. BMC Dermatol. 2012;12:18.PubMedCrossRefGoogle Scholar
  28. 28.
    Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72(1):67–72.PubMedGoogle Scholar
  29. 29.
    Chan R, Park KC, Lee MH, Lee ES, Chang SE, Leow YH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008;159:697–703.PubMedGoogle Scholar
  30. 30.
    Arellano I, Cestari T, Ocampo-Candiani J, et al. Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-lasting clinical severity. J Eur Acad Dermatol Venereol. 2012;26(5):611–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Guevara IL, Pandya AG. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol. 2003;42(12):966–72.PubMedCrossRefGoogle Scholar
  32. 32.
    Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg. 1999;25(4):282–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Lim JT, Tham SN. Glycolic acid peels in the treatment of melasma among Asian women. Dermatol Surg. 1997;23:177–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Hurley ME, Guevara IL, Gonzales RM, Pandya AG. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol. 2002;138:1578–82.PubMedCrossRefGoogle Scholar
  35. 35.
    Faghihi G, Shahingohar A, Siadat AH. Comparison between 1% tretinoin peeling versus 70% glycolic acid peeling in the treatment of female patients with melasma. J Drugs Dermatol. 2011;10(12):1439–42.PubMedGoogle Scholar
  36. 36.
    Ilknur T, Bicak MU, Demirtasoglu M, et al. Glycolic acid peels versus amino fruit acid peels in the treatment of melasma. Dermatol Surg. 2010;36(4):490–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Ejaz A, Raza N, Iftikhar N, Muzzafar F. Comparison of 30% salicylic acid with Jessner’s solution for superficial chemical peeling in epidermal melasma. J Coll Physicians Surg Pak. 2008;18:205–8.PubMedGoogle Scholar
  38. 38.
    Kodali S, Guevara IL, Carrigan CR, et al. A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women. J Am Acad Dermatol. 2010;63(6):1030–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Azzam OA, Leheta TM, Naqui NA, Shaarawy E, Hay RM, Hilal RF. Different therapeutic modalities for the treatment of melasma. J Cosmet Dermatol. 2009;8(4):275–81.PubMedCrossRefGoogle Scholar
  40. 40.
    Wang CC, Hui CY, Sue YM, Wong WR, Hong HS. Intense pulsed light for the treatment of refractory melasma in Asian persons. Dermatol Surg. 2004;30(9):1196–200.PubMedCrossRefGoogle Scholar
  41. 41.
    Goldman MP, Gold MH, Palm MD, et al. Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma. Dermatol Surg. 2011;37(2):224–33.PubMedCrossRefGoogle Scholar
  42. 42.
    Figueiredo SL, Trancoso SS. Single-session intense pulsed light combined with stable fixed-dose triple combination topical therapy for the treatment of refractory melasma. Dermatol Ther. 2012;25:477–80.CrossRefGoogle Scholar
  43. 43.
    Wattanakrai P, Mornchan R, Eimputh S. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians. Dermatol Surg. 2012;36:76–87.CrossRefGoogle Scholar
  44. 44.
    Park KY, Kim DH, Kim HK, et al. A randomized, observer-blinded, comparison of combined 1064-nm Q-switched neodymium-doped yttrium-aluminum-garnet laser plus 30% glycolic acid peel vs. laser monotherapy to treat melasma. Clin Exp Dermatol. 2011;36:864–70.PubMedCrossRefGoogle Scholar
  45. 45.
    Kar HK, Gupta L, Chauhan A. A comparative study on efficacy of high and low fluence Q-switched Nd:YAG laser and glycolic acid peel in melasma. Indian J Dermatol Venereol Leprol. 2012;78:165–71.PubMedCrossRefGoogle Scholar
  46. 46.
    Passeron T, Fontas E, Kang HY, et al. Melasma treatment with pulsed-dye laser and triple combination cream: a prospective, randomized, single-blind, split-face study. Arch Dermatol. 2011;147:1106–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Hong SP, Han SS, Choi SJ, et al. Split-face comparative study of 1550 nm fractional photothermolysis and trichloracetic acid 15% chemical peeling for facial melasma in Asian skin. J Cosmet Laser Ther. 2012;14:81–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Wind BS, Kroon MW, Meesters AA, et al. Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study. Lasers Surg Med. 2010;42:607–12.PubMedCrossRefGoogle Scholar
  49. 49.
    Kroon MW, Wind BS, Beek JF, et al. Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. J Am Acad Dermatol. 2011;64:516–23.PubMedCrossRefGoogle Scholar
  50. 50.
    Lynde CB, Kraft JN, Lynde CW. Topical treatments for melasma and postinflammatory hyperpigmentation. Skin Therapy Lett. 2006;11:1–6.PubMedGoogle Scholar
  51. 51.
    Pandya AG, Hynan LS, Bhore R, et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011;64:78–83.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.State University of New York Downstate Medical CenterBrooklynUSA
  2. 2.Department of DermatologyUniversity of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations